Abstract: Objective To discuss the value of the repeat plasmakinetic resection(Re-PKRBt) in non-muscular invasive bladder tumor. Methods A retrospective analysis was performed on 113 patients with non-muscular invasive bladder tumor who underwent plasmakinetic resection of bladder tumor in the Department of Urology, the First Affiliated Hospital of Bengbu Medical College from July 2017 to January 2019. Among them, 43 patients who underwent Re-PKRBt 4-6 weeks after first plasmakinetic resection were in observation group, while the remaining 70 patients who underwent single plasmakinetic resection were in control group. The following clinical data were recorded and analyzed, including the general data:gender, age, BMI, tumor size, number, preoperative staging, and pathological grading; the operation related information:indwelling catheterization time, intraoperative and postoperative complications, etc.; the postoperative pathological and prognostic data:positive rate of Re-PKRBt, postoperative pathological staging of the two groups of patients and local recurrence rate after 12 months of follow-up, etc. Results There was no significant difference between the two groups in general information and operation related information(all P>0.05). In the observation group, 3 patients(6.98%) showed urothelial tumor cells after Re-PKRBt. There was no significant difference concerning the invasion rate of muscle layer between first plasmakinetic resection in the observation group and the control group(6.98% vs. 7.14%). The invasion rate of muscle layer after secondary plasmakinetic resection in the observation group was significantly higher than that of the control group(20.93% vs. 7.14%), and the difference was statistically significant(P<0.05). The recurrence rate of the observation group was significantly lower than that of the observation group(2.94% vs. 18.46%), and the difference was statistically significant(P<0.05). Conclusion Re-PKRBt can remove tumor tissues to the maximum extent, provide accurate pathological staging and reduce recurrence rate, and increase of intraoperative and postoperative complications is insignificantly. Re-PKRBt for non-muscular invasive bladder tumors can benefit the patients and is worthy of clinical promotion.